RespireRx Pharmaceuticals Inc (RSPI)

[drfreely]

Could be party to deal got cold feet after the trail data was out, or could be management's the one holding out for a better deal after the December results are published, could also be they never had a deal in the first place and the trial was a hail Mary. RSPI's not really in the driver's seat with what they now have. Unfortunately that's the way it goes in the world of small biotech. Many examples come to mind, recently IMGN had to do a secondary when the stock was already at a 52 week low on the failure of an ovarian cancer trial. Shareholders now have to wait at least two more years to see if they can pull a rabbit out of their hat with a new trial, and a huge cash burn every month. Chef was right about one thing when he called RSPI a "lottery ticket." Manuso, Margolis and Lippa are a great team with a real world track record, but they are fighting an uphill battle with this company.